ITF Therapeutics Unveils Promising Findings at 2026 MDA Clinic Conference

ITF Therapeutics Unveils Promising Findings at 2026 MDA Clinical Conference

In an exciting announcement, ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco specializing in rare diseases, revealed that it will present critical research at the upcoming Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, scheduled for March 8-11, 2026, in Orlando, Florida. This year, the company showcases one oral presentation alongside nine poster presentations that underline significant findings related to the treatment of Duchenne muscular dystrophy (DMD).

The oral presentation, led by Dr. Aravindhan Veerapandiyan, focuses on the efficacy and rationale behind adopting a weight-based flexible dosing regimen for their primary drug, givinostat. This innovative approach aims to optimize the doses administered to patients, aligning them more closely with individual patient needs, as highlighted during the pivotal Phase 3 EPIDYS trial. The evaluation criteria included the time taken to complete the four-stair climb test and scores on the North Star Ambulatory Assessment, both essential measures of patient functionality in clinical trials.

Among the poster presentations, one of the notable studies discusses long-term safety observations and insights into disease progression observed in patients treated with givinostat. The data underscores the drug's potential in reducing the decline of muscle contractile area, a significant concern for those with DMD. The findings reflect an encouraging trend towards improving the quality of life for young patients afflicted by this devastating condition.

Additionally, the conference will feature encore poster presentations that delve into the vital aspects of cardiac safety data from the EPIDYS trial, further expanding the understanding of the long-term safety of givinostat in ambulant DMD patients. With insights on the simplified dosing regimen, the presentations promise to enrich ongoing dialogues about the optimal treatment strategies in managing DMD.

"Our journey since ITF Therapeutics' inception has been profoundly influenced by the experiences and voices of those living with Duchenne and their families. The MDA Clinical and Scientific Conference serves as a critical platform for us to gather insights from the community on their evolving needs and priorities," noted Matt Trudeau, President of ITF Therapeutics. He expressed excitement for the opportunity to present their latest findings, which will further the discussion on the efficacy and safety of DUVYZAT, their FDA-approved treatment for DMD.

During the conference, ITF Therapeutics will also host an educational forum titled Clinical Perspectives on HDAC Inhibition in Duchenne Muscular Dystrophy. This session will be moderated by Dr. Omer A. Abdul Hamid, a renowned neuromuscular specialist, who will share perspectives on the unmet needs within the DMD treatment landscape while emphasizing the role of histone deacetylase (HDAC) inhibition as a therapeutic strategy.

As ITF Therapeutics continues its mission to prioritize patient-centric care, the data presentations at the MDA conference promise to shine a light on the therapeutic potential that exists for DMD, reaffirming the company's commitment to driving innovation in rare disease treatment and enhancing the lives of those affected.

The expectations for this conference are high, and numerous advocates, healthcare professionals, and researchers are anticipated to engage in meaningful discussions that could significantly influence future treatment pathways for DMD. As stakeholders in this crucial dialogue come together, ITF Therapeutics stands at the forefront of advancing therapies that hold promise for those grappling with the challenges posed by muscular dystrophy.

About DUVYZAT® (givinostat)
DUVYZAT is recognized as a histone deacetylase (HDAC) inhibitor approved by the U.S. FDA for the treatment of patients six years and older who are living with DMD. It acts by inhibiting the overactivity of HDAC, which is linked to chronic muscle inflammation and diminished muscle repair.

For more information about ITF Therapeutics and its commitment to developing innovative treatment solutions for rare diseases, please visit www.itftherapeutics.com.